Table 2.
Characteristics of included studies
| Study | Year | N | Sex (Female, %) | Mean age | Treatment | N | Exudative RAM (%) | Mean Interval (m) | Baseline LogMAR VA (mean VA in decimal) | Baseline CMT (μm) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Palestine | 1982 | 31 | 22(71) | 68.0 | Observation | 25 | 18(72) | 35.4 | 0.63 ± 0.71 (0.23) | NA | |
| Laser | 6 | 6(100) | 36.1 | 0.48 ± 0.07 (0.33) | NA | ||||||
| Abdel | 1986 | 21 | 15(71) | 68.7 | Observation | 10 | 4(40) | 23.5 | 0.73 ± 0.49 (0.19) | NA | |
| Laser | 11 | 9(82) | 38.8 | 0.92 ± 0.75 (0.12) | NA | ||||||
| Brown | 1994 | 42 | NA | 70.0 | Observation | 26 | 24(92) | 39.5 | 1.08 ± 0.91 (0.08) | NA | |
| Laser | 16 | 13(81) | 42.9 | 1.08 ± 0.71 (0.08) | NA | ||||||
| Moosavi | 2006 | 10 | 6(60) | 71.0 | Observation | 9 | 5(56) | 4.2 | 0.69 ± 0.86 (0.2) | NA | |
| 81.0 | Laser | 1 | 1(100) | 4 | 1 (0.1) | NA | |||||
| Tsujikawa | 2009 | 13 | 10(77) | 74.3 | Observation | 2 | 2(100) | 8 | 0.41 ± 0.16 (0.39) | 418.00 ± 145.66 | |
| Laser | 11 | 6(55) | 18 | 0.50 ± 0.27 (0.32) | 438.55 ± 130.33 | ||||||
| Cho | 2013 | 23 | 19(82) | 71.0 | Observation | 12 | 2(17) | 10.5 | 1.36 ± 0.72 (0.04) | 367.00 ± 105.68 | |
| Anti-VEGF | 11 | 4(36) | 11.2 | 0.86 ± 0.56 (0.14) | 466.73 ± 128.86 | ||||||
| Koinzer | 2015 | 31 | 22(71) | 75.4 | Observation | 16 | 1(6) | 31.3 | 0.48 ± 0.40 (0.33) | NA | |
| Laser | 15 | 6(40) | 37.2 | 0.55 ± 0.37 (0.28) | NA | ||||||
| Meyer | 2015 | 27 | 22(81) | 76.5 | Observation | 14 | 7(50) | 21.8 | 0.79 ± 0.59 (0.16) | NA | |
| Laser | 13 | 0(0) | 25.1 | 1.14 ± 0.70 (0.72) | NA | ||||||
| Cahuzac | 2016 | 12 | 10(83) | 75.1 | Observation | 5 | 1(20) | 7.7 | 1.36 ± 0.92 (0.04) | 561.60 ± 269.72 | |
| Laser | 3 | 3(100) | 7.7 | 0.50 ± 0.17 (0.32) | 494.67 ± 108.09 | ||||||
| Anti-VEGF | 4 | 4(100) | 7.7 | 1.50 ± 0.42 (0.03) | 735.50 ± 184.21 | ||||||
| PUMCH | 2022 | 14 | 11(79) | 71.6 | Observation | 5 | 2(40) | 9 | 0.18 ± 0.20 (0.66) | 260.40 ± 89.98 | |
| Laser | 4 | 4(100) | 2.75 | 0.58 ± 0.33 (0.26) | 377.50 ± 85.25 | ||||||
| Anti-VEGF | 5 | 1(20) | 5.6 | 1.16 ± 0.78 (0.07) | 490.20 ± 210.50 | ||||||
| Total | 224 | NA | 72.4 ± 8.9 | Observation | 124 | 66(53) | 27 | 0.82 ± 0.75 (0.14) | 389.58 ± 175.27 | ||
| Laser | 80 | 48(60) | 24.6 | 0.74 ± 0.66 (0.18) | 407.50 ± 103.03 | ||||||
| Anti-VEGF | 20 | 9(45) | 8.9 | 1.11 ± 0.63 (0.07) | 500.74 ± 177.76 | ||||||
CMT Central macular thickness, NA Not applicable, VA Visual acuity